



LAO PEOPLE 'S DEMOCRATIC REPUBLIC
PEACE INDEPENDENCE DEMOCRACY UNITY PROSPERITY

MINISTRY OF HEALTH
FOOD AND DRUG DEPARTMENT
TEL (856 21) 214013, 214014
FAX: (856 21) 214015.

Certificate of Drug Registration
Registration Number:06-LM-10029-26

ALILAZTINI

Dosage Form	TABLET, FILM COATED
Active Ingredients	LAZERTINIB MESYLATE 96.46mg
Description	This product is a Yellow film coated tablets, oval, HDPE Bottle, 90 Tablets per bottle.
Size of packaging unit	90 TABLETS
Indications	See Annex
Manufacturer	LAOS ALLIANCE PHARMACEUTICAL GROUP COMPANY SAYSETHA DEVELOPMENT ZONE, SAYSETHA DISTRICT, VIENTIANE CAPITAL, LAO PDR

This Certificate is issued to attest that the product described above has met the minimum standards required for drug registration undertaken by the Food and Drug Department in Lao PDR.

This certificate expires, unless previously suspended or revoked, on **31 July 2031**

Note: All boxes and packaging for importations must bear the Lao Registration No. **06-LM-10029-26**

At, Vientiane, **03 June 2026**



ໄດຣ. ສຸກສິມຄວນ ຈັນທະມາດ



Registration Number:06-LM-10029-26

ALILAZTINI

ANNEX

INDICATIONS

• ALILAZTINI is a kinase inhibitor indicated in combination with amivantamab for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations

• ALILAZTINI ແມ່ນຢາຢັບຢັງ Kinase (kinase inhibitor) ທີ່ໃຊ້ຮ່ວມກັບ amivantamab ສໍາລັບປິ່ນປົວຄົນເຈັບຜູ້ໃຫຍ່ທີ່ເປັນມະເຮັງປອດຊະນິດຈຸລັງນ້ອຍ (NSCLC) ໃນໄລຍະແຜ່ລາມ ຫຼື ແຜ່ກະຈາຍ, ແລະ ມີການກາຍພັນຂອງຈຸລັງ EGFR ປະເພດ exon 19 deletion ເປັນຕົວຮັບປັດໃຈຂອງການຈະເລີນເຕີບໂຕ ຫຼື ມີການກາຍພັນແທນທີ່ exon 21 L858R substitution

